Dr Yuk Ting Ma MBChB (hons), MRCP, PhD

Institute of Immunology and Immunotherapy
Senior Clinical Lecturer in Hepatobiliary Oncology

Contact details

Address
Institute of Immunology and Immunotherapy
College of Medical and Dental Sciences
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Yuk Ting Ma is a Senior Clinical Lecturer in Hepatobiliary Oncology in the Institute of Immunology and Immunotherapy and an Honorary Consultant in Hepatobiliary Oncology at the University Hospitals Birmingham NHS Foundation Trust.

Her research is focussed on understanding how epigenetic therapies may be used to reverse resistance to chemotherapy and also in understanding the immune responses following treatment in hepatobiliary cancers.

Qualifications

  • PhD, University of Birmingham - 2011
  • MRCP (UK) - 2003
  • MBChB (hons), University of Birmingham - 2000

Biography

Yuk Ting studied Medicine at the University of Birmingham, graduating with honours in 2000. She undertook general medical training in Birmingham gaining Membership of the Royal Colleges of Physicians in 2003. She then undertook specialist training in Medical Oncology in the West Midlands region and was awarded a CRUK Clinical Research Training Fellowship in 2005.

Her PhD investigating smoking- and viral-induced epigenetic changes in cervical epithelia was supervised by Professor Paul Murray and the late Professor Ciaran Woodman, in the University of Birmingham. In 2012, Yuk Ting was appointed as a Senior Clinical Lecturer in Hepatobliary Oncology at the University of Birmingham, and as an Honorary Consultant in Hepatobiliary Oncology at the University Hospitals Birmingham NHS Foundation Trust.

Teaching

Postgraduate supervision

Yuk Ting has supervised the laboratory projects of a number of BMedSci students

If you are interesting in studying any of these subject areas please contact Dr Yuk Ting Ma directly, or for any general doctoral research enquiries, please email mds-gradschool@contacts.bham.ac.uk.

For a full list of available Doctoral Research opportunities, please visit our Doctoral Research programme listings.

Research

The development of resistance to cytotoxic or targeted therapy in a cancer patient greatly limits the effectiveness of available anticancer therapies. A variety of mechanisms of resistance have been identified including enhanced drug metabolism, drug efflux from cancer cells and activation of alternative survival pathways. Recently dynamic chromatin modifications have been identified as a key determinant in the maintenance of subpopulations of cancer cells with high-level resistance to cytotoxic therapy. Dr Ma’s research focuses on understanding how epigenetic drugs may be used to reverse chemotherapy resistance.

Recent experimental studies have also shown that epigenetic drugs can have potent immunomodulating effects and Yuk Ting is also studying the immune responses in patients following treatment, and ultimately whether this may be modulated with epigenetic drugs.

Other activities

  • Member of the NCRI Upper GI CSG

Publications

Recent publications

Article

Razak, RA, Fletcher, P, Kunene, V & Ma, YT 2021, 'Association of gastric acid suppression and sorafenib efficacy in advanced hepatocellular carcinoma', Journal of Clinical Gastroenterology, vol. 55, no. 2, pp. 169-173. https://doi.org/10.1097/MCG.0000000000001375

Virtakoivu, R, Rannikko, JH, Viitala, M, Vaura, F, Takeda, A, Lönnberg, T, Koivunen, J, Jaakkola, P, Pasanen, A, Shetty, S, Jonge, MJAD, Robbrecht, D, Ma, YT, Skyttä, T, Minchom, A, Jalkanen, S, Karvonen, MK, Mandelin, J, Bono, P & Hollmen, M 2021, 'Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: results from a phase I/II clinical trial', Clinical Cancer Research, vol. 27, no. 15, pp. 4205-4220. https://doi.org/10.1158/1078-0432.CCR-20-4862

Johnson, PJ, Dhanaraj, S, Berhane, S, Bonnett, L & Ma, YT 2021, 'The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study', British Journal of Cancer, vol. 125, no. 5, pp. 714-716. https://doi.org/10.1038/s41416-021-01445-3

Ma, YT 2020, 'MTL-CEBPA, a Small Activating RNA Therapeutic Up-Regulating C/EBP-α, in Patients With Advanced Liver Cancer: A First-In-Human, Multi-Centre, Open-Label, Phase I Trial', Clinical Cancer Research.

Kalisvaart, M, Broadhurst, D, Marcon, F, Pande, R, Schlegel, A, Sutcliffe, R, Marudanayagam, R, Mirza, D, Chatzizacharias, N, Abradelo, M, Muiesan, P, Isaac, J, Ma, YT, Mcconville, C & Roberts, K 2020, 'Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study', HPB : the official journal of the International Hepato Pancreato Biliary Association. https://doi.org/10.1016/j.hpb.2020.01.005

Corrie, PG, Qian, W, Basu, B, Valle, JW, Falk, S, Lwuji, C, Wasan, H, Palmer, D, Scott-brown, M, Wadsley, J, Arif, S, Bridgewater, J, Propper, D, Gillmore, R, Gopinathan, A, Skells, R, Bundi, P, Brais, R, Dalchau, K, Bax, L, Chhabra, A, Machin, A, Dayim, A, Mcadam, K, Cummins, S, Wall, L, Ellis, R, Anthoney, A, Evans, J, Ma, YT, Isherwood, C, Neesse, A, Tuveson, D & Jodrell, DI 2020, 'Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma', British Journal of Cancer, vol. 122, no. 12, pp. 1760–1768. https://doi.org/10.1038/s41416-020-0846-2

Palmer, DH, Valle, JW, Ting Ma, Y, Faluyi, O, Neoptolemos, JP, Jensen Gjertsen, T, Iversen, B, Amund Eriksen, J, Møller, A, Aksnes, A, Miller, R & Dueland, S 2020, 'TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial', British Journal of Cancer, vol. 122, no. 7, pp. 971–977. https://doi.org/10.1038/s41416-020-0752-7

Ma, YT 2020, 'Treatment strategies for the optimal management of locally advanced pancreatic adenocarcinoma with curative intent: A systematic review.', Pancreas.

BILCAP study group, Primrose, JN, Fox, RP, Palmer, DH, Malik, HZ, Prasad, R, Mirza, D, Anthony, A, Corrie, P, Falk, S, Finch-Jones, M, Wasan, H, Ross, P, Wall, L, Wadsley, J, Evans, JTR, Stocken, D, Praseedom, R, Ma, YT, Davidson, B, Neoptolemos, JP, Iveson, T, Raftery, J, Zhu, S, Cunningham, D, Garden, OJ, Stubbs, C, Valle, JW & Bridgewater, J 2019, 'Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study', The Lancet Oncology, vol. 20, no. 5, pp. 663-673. https://doi.org/10.1016/S1470-2045(18)30915-X

Dasari, BVM & Ma, YT 2019, 'Development and validation of a risk score to predict the overall survival following surgical resection of hepatocellular carcinoma in non-cirrhotic liver', HPB : the official journal of the International Hepato Pancreato Biliary Association. https://doi.org/10.1016/j.hpb.2019.07.007

Ahsan Javed, M & Ma, YT 2019, 'Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.', Pancreatology, vol. 19, no. 1, pp. 97-104. https://doi.org/10.1016/j.pan.2018.10.003

Ma, YT 2019, 'Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial', JAMA Surgery.

Palmer, DH, Ma, Y, Peck-Radosavljevic, M, Ross, P, Graham, J, Fartoux, L, Deptala, A, Studeny, M, Schnell, D, Hocke, J, Loembe, A-B & Meyer, T 2018, 'A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of Nintedanib vs. Sorafenib in European patients with advanced hepatocellular carcinoma', British Journal of Cancer, vol. 118, pp. 1162-1168. https://doi.org/10.1038/s41416-018-0051-8

Afshar, M, Fletcher, P, Bardoli, A, Ma, Y & Punia, P 2018, 'Non-secretion of AFP and neutrophil lymphocyte ratio as predictors for survival in hepatocellular carcinoma patients treated with sorafenib: a large UK cohort', OncoTarget, vol. 9, no. 24, pp. 16988–16995. https://doi.org/10.18632/oncotarget.24769

Lim, HY, Merle, P, Weiss, K-H, Yau, TCC, Ross, P, Blanc, J-F, Mazzaferro, V, Ma, Y, Yen, C-J, Kocsis, J, Choo, SP, Sukeepaisarnjaroen, W, Gérolami, R, Dufour, J-F, Gane, EJ, Ryoo, B-Y, Peck-Radosavljevic, M, Dao, T, Yeo, W, Lamlertthon, W, Thongsawat, S, Teufel, M, Roth, K, Reis, D, Childs, BH, Krissel, H & Llovet, JM 2018, 'Phase II studies with Refametinib or Refametinib plus Sorafenib in patients with RAS-mutated Hepatocellular Carcinoma', Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-17-3588

View all publications in research portal